Cargando…

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital

OBJECTIVE: To determine the indications, success rate and adverse effects of ceftaroline fosamil treatment in a tertiary hospital. MATERIAL AND METHODS: In total, 84 cases from February 2018 to December 2019 were retrospectively analysed. No exclusion criteria were applied. RESULTS: Eighty-four pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Álvarez, Alicia Alonso, Merino, Lucía Ramos, Corral, Laura María Castelo, Trigo, Ana Padín, Regueiro, Dolores Sousa, Rey, Enrique Míguez, Vidal, Efrén Sánchez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2021
Materias:	Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019472/ https://www.ncbi.nlm.nih.gov/pubmed/33586407 http://dx.doi.org/10.37201/req/119.2020

Ejemplares similares

Use of ceftaroline in complex central nervous system infections
por: Álvarez, Alicia Alonso, et al.
Publicado: (2023)

Ceftaroline Fosamil: A Brief Clinical Review
por: Shirley, Debbie-Ann T., et al.
Publicado: (2013)

Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
por: Johnson, Leonard B., et al.
Publicado: (2019)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application
por: Yim, Juwon, et al.
Publicado: (2016)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis
por: Sotgiu, Giovanni, et al.
Publicado: (2018)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report
por: Jilani, Talha N, et al.
Publicado: (2018)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury
por: Faris, Janie, et al.
Publicado: (2015)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion
por: Riccobene, Todd, et al.
Publicado: (2019)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
por: Torres, Antoni, et al.
Publicado: (2022)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials
por: Wilcox, Mark, et al.
Publicado: (2021)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
por: Sánchez-García, Miguel, et al.
Publicado: (2020)

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
por: Dryden, Matthew, et al.
Publicado: (2016)

Ceftaroline-related acute eosinophilic pneumonia
por: Min, Zaw, et al.
Publicado: (2021)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

A Case of Ceftaroline-Associated Thrombocytopenia
por: Jagadish, Ashwin, et al.
Publicado: (2023)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021)

472 Ceftaroline-induced Neutropenia: Two Case Reports
por: Martin, Kelly E., et al.
Publicado: (2014)

Efficacy and safety of ceftaroline: systematic review and meta-analysis
por: Rosanova, Maria T., et al.
Publicado: (2018)

Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
por: Srinivasan, Aswin, et al.
Publicado: (2021)

2309. Ceftaroline for Central Nervous System and Ocular Infections
por: Siegrist, Emily A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o6o4o7dl25r10rv7197j9n45qt